Isha Mondal

Isha Mondal

Auto-generated profile, based on publicly available information

Isha Mondal

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
IMIsha Mondal
Isha Mondal
ODOishika Das
Oishika Das
RSRaymond Sun
Raymond Sun
JGJian Gao
Jian Gao
BYBohyeon Yu
Bohyeon Yu
WHWinson Ho
Winson Ho
Glioblastoma (GBM) is an immunologically “cold” tumor that does not respond to current immunotherapy. Here, we demonstrate a fundamental role for the α-isoform of the catalytic subunit of protein phosphatase-2A (PP2Ac) in regulating glioma immunogenicity. Genetic ablation of PP2Ac in glioma cells enhanced double-stranded DNA (dsDNA) production and cGAS–type I IFN signaling, MHC-I expression, and tumor mutational burden. In coculture experiments, PP2Ac deficiency in glioma cells promoted dendritic cell (DC) cross-presentation and clonal expansion of CD8+ T cells. In vivo, PP2Ac depletion sensitized tumors to immune-checkpoint blockade and radiotherapy treatment. Single-cell analysis demonstrated that PP2Ac deficiency increased CD8+ T-cell, natural killer cell, and DC accumulation and reduced immunosuppressive tumor-associated macrophages. Furthermore, loss of PP2Ac increased IFN signaling in myeloid and tumor cells and reduced expression of a tumor gene signature associated with worse patient survival in The Cancer Genome Atlas. Collectively, this study establishes a novel role for PP2Ac in inhibiting dsDNA–cGAS–STING signaling to suppress antitumor immunity in glioma. Significance: PP2Ac deficiency promotes cGAS–STING signaling in glioma to induce a tumor-suppressive immune microenvironment, highlighting PP2Ac as a potential therapeutic target to enhance tumor immunogenicity and improve response to immunotherapy.

15 March 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
WHWinson S. Ho
Winson S. Ho
IMIsha Mondal
Isha Mondal
BXBeisi Xu
Beisi Xu
ODOishika Das
Oishika Das
RSRaymond C. Sun
Raymond C. Sun
RLRongze Olivia Lu
Rongze Olivia Lu
STING-Type I interferon (IFN) signaling in myeloid cells plays a critical role in effective antitumor immune responses, but STING agonist as monotherapy has shown limited efficacy in clinical trials. The mechanisms that downregulate STING signaling are not fully understood. Here, we report that Protein phosphatase 2A (PP2A) with its specific B regulatory subunit STRN4 negatively regulated STING-Type I IFN in macrophages. Mice with macrophages PP2A deficiency exhibited reduced tumor progression. The tumor microenvironment showed decreased immunosuppressive and increased IFN-activated macrophages and CD8+ T cells. Mechanistically, we demonstrated that hippo kinase MST1/2 was required for STING activation. STING agonist induced dissociation of PP2A from MST1/2 in normal macrophages, but not in tumor conditioned macrophages. Furthermore, our data showed that STRN4 mediated PP2A binding to and dephosphorylation of hippo kinase MST1/2, resulting in stabilization of YAP/TAZ to antagonize STING activation. In human GBM patients, YAP/TAZ was highly expressed in tumor-associated macrophages but not in non-tumor macrophages. We also demonstrated that PP2A/STRN4 deficiency in macrophages reduced YAP/TAZ expression and sensitized tumor conditioned macrophages to STING stimulation. In summary, we demonstrated that PP2A/STRN4-YAP/TAZ is a previously unappreciated mechanism that mediate immunosuppression in tumor-associated macrophages and targeting PP2A/STRN4-YAP/TAZ axis can sensitize tumors to immunotherapy.

24 November 2025
Verified
Other
Open access
IMIsha Mondal
Isha Mondal
ODOishika Das
Oishika Das
RSRaymond Sun
Raymond Sun
JGJian Gao
Jian Gao
BYBohyeon Yu
Bohyeon Yu
WHWinson Ho
Winson Ho
Supplementary Text Figs. S1 to S8 Tables S1 to S3

24 November 2025
Verified
Other
Open access
IMIsha Mondal
Isha Mondal
ODOishika Das
Oishika Das
RSRaymond Sun
Raymond Sun
JGJian Gao
Jian Gao
BYBohyeon Yu
Bohyeon Yu
WHWinson Ho
Winson Ho
Cluster defining genes from scRNAseq data

16 September 2024
Verified
Other
Open access
IMIsha Mondal
Isha Mondal
ODOishika Das
Oishika Das
RSRaymond Sun
Raymond Sun
JGJian Gao
Jian Gao
BYBohyeon Yu
Bohyeon Yu
WHWinson Ho
Winson Ho
Glioblastoma (GBM) is an immunologically “cold” tumor that does not respond to current immunotherapy. Here, we demonstrate a fundamental role for the α-isoform of the catalytic subunit of protein phosphatase-2A (PP2Ac) in regulating glioma immunogenicity. Genetic ablation of PP2Ac in glioma cells enhanced double stranded DNA (dsDNA) production and cGAS-type I interferon (IFN) signaling, MHC-I expression, and tumor mutational burden. In co-culture experiments, PP2Ac deficiency in glioma cells promoted dendritic cell (DC) cross presentation and clonal expansion of CD8+ T cells. In vivo, PP2Ac depletion sensitized tumors to immune checkpoint blockade and radiotherapy treatment. Single cell analysis demonstrated that PP2Ac deficiency increased CD8+ T cell, NK cell, and DC accumulation and reduced immunosuppressive tumor associated macrophages. Furthermore, loss of PP2Ac increased IFN signaling in myeloid and tumor cells and reduced expression of a tumor gene signature associated with worse patient survival in TCGA. Collectively, this study establishes a novel role for PP2Ac in inhibiting dsDNA-cGAS-STING signaling to suppress anti-tumor immunity in glioma.

16 September 2024
Verified
Other
Open access
PDF file
IMIsha Mondal
Isha Mondal
ODOishika Das
Oishika Das
RSRaymond Sun
Raymond Sun
JGJian Gao
Jian Gao
BYBohyeon Yu
Bohyeon Yu
WHWinson Ho
Winson Ho
Supplementary Text Figs. S1 to S8 Tables S1 to S3